Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

QNRX vs FRMM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

QNRX Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 8–1 Matrix Metrics)

QNRX Overall Winner 6-Pillar Tally: QNRX 3 – 1 FRMM (2 Tie) Matrix Metrics: QNRX 8 – 1 FRMM

As of Nov 20, 2026, Quoin Pharmaceuticals, Ltd. (QNRX) is the stronger overall head-to-head candidate over FRMM (FRMM) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). QNRX carries a Unified Composite Score of 46.1/100 (HOLD) at $3.28 (N/M Forward P/E, 0.0% operating margin), whereas FRMM carries 42.5/100 (HOLD) at $1.92 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: QNRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5); meanwhile FRMM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About QNRX vs FRMM
QNRX NASDAQ Head-to-Head Winner
Quoin Pharmaceuticals, Ltd. American Depositary Shares
Pharmaceutical Preparations
$3.28
-2.35% 1D
Market Cap $16.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.34β · 74% Vol
Unified Composite Score
46.1 / 100 HOLD
Tech 38.0 Fund 47.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.8%), weak momentum, RSI 32
RSI-14: 32.5 · SMA20: $3.81 · SMA50: $4.64
FRMM US Equity
FRMM
Institutional Equity
$1.92
-4.48% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.28β · 107% Vol
Unified Composite Score
42.5 / 100 HOLD
Tech 35.0 Fund 44.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.4%), weak momentum, RSI 25
RSI-14: 24.5 · SMA20: $2.90 · SMA50: $3.80

6-Pillar Scorecard Institutional Category Breakdown (QNRX 3 – 1 FRMM)

Columns: Metric · QNRX · FRMM
1. Valuation Multiples QNRX
Forward P/E N/M N/M
Trailing P/E 7.6x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale QNRX
Revenue Growth (YoY) +0.0% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) N/A N/A
Market Cap $16.1M N/A
3. Profitability & Quality QNRX
Gross Margin N/A N/A
Operating Margin 0.0% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -142.6% N/A
4. Balance Sheet & Cash Flow FRMM
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $5.97 Book/Sh · -142.6% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: QNRX (8) vs FRMM (1)
Institutional Metric QNRX FRMM Criterion Row Edge
Market Capitalization
Scale
$16.1M N/A Larger Scale QNRX
Trailing P/E Ratio
Valuation
7.6x N/M Lower Multiple QNRX
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% N/A Higher Growth QNRX
Operating Margin (TTM)
Profitability
0.0% N/A Higher Margin QNRX
Net Profit Margin
Profitability
0.0% N/A Higher Margin QNRX
Return on Equity (ROE)
Capital Efficiency
-142.6% N/A Higher ROE QNRX
52-Week Range Position
Momentum
0% ($3–$24) 3% ($2–$7) Stronger Trend FRMM
Beta / 30D Volatility
Risk Regime
1.34β · 74% Vol 2.28β · 107% Vol Lower Realized Risk QNRX
Unified Institutional Score
Composite Signal
46.1 / 100 (HOLD) 42.5 / 100 (HOLD) Higher Composite QNRX
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($5.97 Book/Sh · -142.6% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon QNRX +24.14 pp
QNRX: -18.2% · FRMM: -42.34%
3M Horizon QNRX +28.68 pp
QNRX: -39.48% · FRMM: -68.16%
6M Horizon QNRX +26.47 pp
QNRX: -31.24% · FRMM: -57.71%
1Y Horizon FRMM +16.99 pp
QNRX: -61.5% · FRMM: -44.51%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on QNRX vs FRMM. Trailing 12-month operating profitability (QNRX 0.0% vs FRMM N/A) and valuation multiples (QNRX N/M vs FRMM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

QNRX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-142.6% · N/M
FRMM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
QNRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact QNRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FRMM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FRMM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
QNRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $16.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FRMM Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ QNRX vs FRMM Key Questions & Quantitative Answers

As of Nov 20, 2026, Quoin Pharmaceuticals, Ltd. (QNRX) is the stronger overall head-to-head candidate over FRMM (FRMM) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). QNRX carries a Unified Composite Score of 46.1/100 (HOLD) at $3.28 (N/M Forward P/E, 0.0% operating margin), whereas FRMM carries 42.5/100 (HOLD) at $1.92 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: QNRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5); meanwhile FRMM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

QNRX leads the Growth & Scale pillar: QNRX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with FRMM at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, QNRX generates N/A in USD-normalized revenue versus N/A for FRMM. In operating R&D and SG&A reinvestment, QNRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FRMM.

QNRX screens cheaper on headline valuation multiples. QNRX trades at N/M Forward P/E, 7.6x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas FRMM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against QNRX (-142.6% ROE) versus FRMM (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, QNRX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 74% Vol realized risk). By comparison, FRMM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.28β · 107% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.